BCYC - Bicycle Therapeutics Ltd

BCYC - Bicycle Therapeutics Ltd

https://www.bicycletherapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Bicycle Therapeutics ( NASDAQ:BCYC ) , Alumis ( NASDAQ:ALMS )

Benzinga • 9 months ago • score: -0.13

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday. Shares of Candel Therapeutics, Inc. CADL fell sharply in today's pre-market trading after the company announced the pricing of public offering.

Bicycle Therapeutics ( BCYC ) Soars 5.7%: Is Further Upside Left in the Stock?

Zacks Commentary • 11 months ago • score: 0.10

Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone - Bicycle Therapeutics ( NASDAQ:BCYC )

Benzinga • 1 year ago • score: 0.44

RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.

What Makes Bicycle Therapeutics ( BCYC ) a New Buy Stock

Zacks Commentary • 1 year, 1 month ago • score: 0.34

Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.

52W High

$28.67

52W Low

$6.10

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.41

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.14

EV/Revenue (<3 favorable)

21.22

P/S (TTM) (<3 favorable)

25.74

P/B (<3 favorable)

0.74

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.40%

Institutions (25–75% balanced)

88.36%

Shares Outstanding

49,868,600

Float

1,884,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

19,281,000

Gross Profit (TTM)

-208,848,992

EPS (TTM)

-3.52

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-29.66%

ROE (TTM) (>15% strong)

-0.31%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.69

Momentum

Bearish momentum

Value

-0.1785

Previous

-0.1911

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025